ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know

Key Takeaways ARCT shares fell after interim phase II data for ARCT-032 showed no meaningful day 1-28 FEV1 improvement.Exploratory analysis found modest day 42 FEV1 gains and showed mucus-reduction trends in most patients.ARCT is advancing dose escalation and plans a 12-week study of ARCT-032 in up to 20 CF patients in 2026.Shares of Arcturus Therapeutics (ARCT) have plunged 59.4% in the past three months. The massive stock price drop was primarily due to the mixed nature of the interim results reported by ...